PROVECTUS PV-10 INTERIM PHASE 2 SAFETY AND EFFICACY RESULTS ARE AS GOOD AS OR BETTER THAN PHASE 1 RESULTS

2009-03-21 アップロード · 116 視聴

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that the interim safety and efficacy results from the first 20 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma are as good as or better than Phase 1 data. Additionally, extended Phase 1 survival data was reported.

To view Multimedia News Release go to http://www.prnewswire.com/mnr/pvct/37429/

tag·Provectus,Pharmaceuticals,PV,10,metastatic,melanoma,Phase,2,study,Multivu

非会員の場合は、名前/パスワードを入力してください。

書き込む
今日のアクセス
24
全体アクセス
134,608
チャンネル会員数
35

My Video

リスト形式で表示 碁盤形式で表示